Q4 2018 Earnings Estimate for Achaogen Inc (AKAO) Issued By SunTrust Banks
Achaogen Inc (NASDAQ:AKAO) – Research analysts at SunTrust Banks dropped their Q4 2018 earnings per share (EPS) estimates for Achaogen in a research report issued on Tuesday, November 13th, Zacks Investment Research reports. SunTrust Banks analyst E. Nash now expects that the biopharmaceutical company will post earnings per share of ($0.82) for the quarter, down from their prior forecast of ($0.74). SunTrust Banks has a “Hold” rating and a $3.00 price objective on the stock. SunTrust Banks also issued estimates for Achaogen’s Q1 2019 earnings at ($0.58) EPS, Q2 2019 earnings at ($0.54) EPS, Q3 2019 earnings at ($0.55) EPS, Q4 2019 earnings at ($0.59) EPS, FY2019 earnings at ($2.27) EPS, FY2020 earnings at ($2.24) EPS, FY2021 earnings at ($1.67) EPS and FY2022 earnings at ($1.28) EPS.
AKAO has been the subject of a number of other research reports. Stifel Nicolaus lowered shares of Achaogen from a “buy” rating to a “hold” rating in a research report on Friday, November 9th. ValuEngine raised shares of Achaogen from a “sell” rating to a “hold” rating in a research report on Friday, September 7th. Zacks Investment Research lowered shares of Achaogen from a “buy” rating to a “hold” rating in a research report on Wednesday, October 17th. HC Wainwright reaffirmed a “neutral” rating and set a $3.00 price objective (down previously from $19.00) on shares of Achaogen in a research report on Monday, November 12th. Finally, Gabelli lowered shares of Achaogen from a “buy” rating to a “hold” rating in a research report on Friday, November 9th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the stock. Achaogen has a consensus rating of “Hold” and a consensus target price of $9.25.
A number of large investors have recently bought and sold shares of AKAO. JPMorgan Chase & Co. raised its position in Achaogen by 2,745.0% in the third quarter. JPMorgan Chase & Co. now owns 294,768 shares of the biopharmaceutical company’s stock worth $1,176,000 after purchasing an additional 284,407 shares in the last quarter. AXA grew its stake in Achaogen by 31.4% during the third quarter. AXA now owns 903,425 shares of the biopharmaceutical company’s stock worth $3,605,000 after buying an additional 215,989 shares during the last quarter. SG Americas Securities LLC bought a new stake in Achaogen during the third quarter worth about $823,000. Bank of America Corp DE grew its stake in Achaogen by 274.7% during the second quarter. Bank of America Corp DE now owns 198,204 shares of the biopharmaceutical company’s stock worth $1,717,000 after buying an additional 145,305 shares during the last quarter. Finally, Granahan Investment Management Inc. MA bought a new stake in Achaogen during the second quarter worth about $1,220,000. 45.59% of the stock is owned by hedge funds and other institutional investors.
In other Achaogen news, major shareholder Robert W. Duggan purchased 157,760 shares of the company’s stock in a transaction that occurred on Tuesday, November 27th. The stock was purchased at an average price of $1.79 per share, with a total value of $282,390.40. Following the completion of the transaction, the insider now directly owns 8,343,945 shares of the company’s stock, valued at approximately $14,935,661.55. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Robert W. Duggan purchased 80,175 shares of the company’s stock in a transaction that occurred on Friday, November 23rd. The stock was acquired at an average cost of $1.89 per share, with a total value of $151,530.75. Following the transaction, the insider now directly owns 8,343,945 shares of the company’s stock, valued at $15,770,056.05. The disclosure for this purchase can be found here. Insiders purchased 242,583 shares of company stock valued at $441,451 in the last three months. Company insiders own 7.80% of the company’s stock.
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Recommended Story: How are the companies in the S&P 500 selected?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.